NCT06828211View on ClinicalTrials.gov

Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

February 9, 2025

Study Completion Date

March 31, 2025

Conditions

Heart FailureArterial HypertensionOsteopeniaMenopause

Interventions

DIETARY_SUPPLEMENT

Trans-resveratrol extract from Polygonum Cuspidatum

OTHER

Placebo

Trial Locations (1)

03057

Omnifarma LLC, Kyiv

All Listed Sponsors

lead

OMNIFARMA LLC

INDUSTRY

NCT06828211 - Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD | Biotech Hunter | Biotech Hunter